Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

TCGA-L9-A7SV-01A-11R-A39D-07

· cohortA1

4990e634-f7ab-57a7-918a-25fdbd7860c2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA1
subtype
cohortA1
age_years
69

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • SPERMATOGENESIS+0.140
  • KRAS_SIGNALING_DN+0.080
  • BILE_ACID_METABOLISM+0.070
  • MITOTIC_SPINDLE+0.020
  • MYC_TARGETS_V2-0.010
  • NOTCH_SIGNALING-0.020
  • PEROXISOME-0.090
  • E2F_TARGETS-0.110
  • MYOGENESIS-0.110
  • HEME_METABOLISM-0.120

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
  • ANGIOGENESIS-0.510
  • INTERFERON_GAMMA_RESPONSE-0.470
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
  • ALLOGRAFT_REJECTION-0.460
  • INTERFERON_ALPHA_RESPONSE-0.460
  • APICAL_SURFACE-0.440
  • COMPLEMENT-0.440
  • TGF_BETA_SIGNALING-0.440
  • INFLAMMATORY_RESPONSE-0.430

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1TCGA-FJ-A3ZF-01A-11R-A23N-07
bladder-landscape@3
0.943
2SRR650166
bladder-landscape@3
0.937
3SRR1456514
brain-umap@2
GTEX0.936
4SRR1377984
brain-umap@2
GTEX0.935
5SRR607967
brain-umap@2
GTEX0.934
6SRR1474754
brain-umap@2
GTEX0.930
7a50c02ec-6ba9-4678-990d-6c74a8e9b7b5
colon-landscapes@1
0.930
8SRR1459033
brain-umap@2
GTEX0.929
9SRR1341605
brain-umap@2
GTEX0.925
10SRR1478096
brain-umap@2
GTEX0.924

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 4 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
SPERMATOGENESIS0.140Inavolisib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered
BILE_ACID_METABOLISM0.070Inavolisib— uncovered
MITOTIC_SPINDLE0.020Inavolisib— uncovered